Computer simulations using GastroPlus™ to justify a biowaiver for etoricoxib solid oral drug products
Arthur Okumu, Marie Di Maso, Raimar Löbenberg · European Journal of Pharmaceutics and Biopharmaceutics · 2008
Cited by 117 works. doi:10.1016/j.ejpb.2008.10.019
Authors
References
- A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
- Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System
- Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms
- Evaluation of Various Dissolution Media for Predicting In Vivo Performance of Class I and II Drugs
- Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract1PII of original article: S0169-409X(96)00487-5. The article was originally published in Advanced Drug Delivery Reviews 25 (1997) 3–14.1
- Physicochemical and Physiological Mechanisms for the Effects of Food on Drug Absorption: The Role of Lipids and pH
- Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions
- WHO Expert Committee on Specifications for Pharmaceutical Preparations.
- Absorption Potential: Estimating the Fraction Absorbed for Orally Administered Compounds
- Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2